ArticleJournal of the National Cancer Institute2026
Early-detection and prevention effects of screening sigmoidoscopy: evidence from randomized trials revisited.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endoscopic screening for colorectal cancer: efficacy versus effectiveness.Journal of the National Cancer Institute · 2026Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
backgroundLarge-scale randomized controlled trials (RCTs) have established compelling evidence that screening by flexible sigmoidoscopy reduces colorectal cancer (CRC) incidence. Reported incidence results include cancers that were already prevalent and yet undiagnosed, but no longer preventable at screening. We aimed to derive, disentangle, and fully disclose early-detection and long-term prevention effects of screening sigmoidoscopy from published trial results.
methodsWe used data from 3 large-scale RCTs from the United Kingdom (UKFSST), Italy (SCORE), and the United States (PLCO), which included a total number of 359 198 participants. For each trial and each length of follow-up, we derived the numbers and proportions of CRC cases that were either early detected or prevented among screening attenders.
resultsIn the UKFSST, which reported the longest follow-up data, screening sigmoidoscopy prevented 64% (95% CI = 59% to 69%) of incident distal CRC that would have been expected in the absence of screening during a median of 21.3 years. Within follow-up periods between 10 and 12 years, the proportions of distal CRC cases that were either early detected or prevented among screening users ranged between 67% (95% CI = 61% to 72%) in the PLCO and 80% (95% CI = 68% to 89%) in the SCORE trial, with approximately equal shares of early-detected and prevented cases in the SCORE and the PLCO trials, and a higher share of prevented cases in the UKFSST.
conclusionsA single screening sigmoidoscopy prevents 2 out of 3 incident cancers in the distal colon and rectum over a period of more than 20 years, on top of early-detecting prevalent cases at screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.